Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06714591Phase 1Terminated
- Sponsor
- SystImmune Inc.
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BL-M11D1 in acute myeloid leukemia (AML) (2 cohorts), sponsored by SystImmune Inc. Primary endpoints: Dose-Limiting Toxicities at 1 year, Serious Adverse Events and Treatment-Emergent Adverse Events at 1 year and 1 more. Started Dec 2024; status: terminated.
02
Drugs
BL-M11D1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06714591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714591.